We identified that MAP4K3 is the key drug resistance relative gene in hepatocellular carcinoma and provide an experimental basis for seeking biomarkers to develop effective therapy for patients who are not qualified for surgical intervention. The gene discussed is MAP4K3; the disease is hepatocellular carcinoma.